Indeed, these insights pave the way to further investigations aimed to figure out whether compound 4 acts on CRC cell models resistant to EGFR inhibitors with high selectivity, and if so, to elucidate the mechanism by which the anti-proliferative activity occurs. Here, EGFR is linked to colorectal carcinoma.